Patent 9149478 was granted and assigned to Boehringer Ingelheim on October, 2015 by the United States Patent and Trademark Office.
The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.